Our study | Pilot study: ThuLEP [15] | Pilot study: TURP [15] | |||||
---|---|---|---|---|---|---|---|
Total | Malignancy | Benign | P-value** | P-value** | |||
Patients | 125 | 15 | 110 | 29 | 30 | ||
Age, years | 71.85 ± 8.89 | 78.81 ± 7.17 | 71.07 ± 8.68 | 76.1 ± 9.4 | 0.02 | 72.6 ± 7.4 | 0.62 |
PSA level, ng/mL | 18.40 ± 37.35 | 37.03 ± 60.34 | 16.14 ± 33.26 | 5.0 ± 5.4 | 0.49 | 8.3 ± 7.9 | 0.47 |
Anticoagulant agent use | 5 (4%) | 0 | 5 (4.45%) | 15 (51.7%) | 6 (20.0%) | ||
Estimated prostate volume, mL | 106.80 ± 45.77 | 106.80 ± 70.76 | 106.40 ± 41.25 | 57.2 ± 25.1 | < 0.01 | 64.7 ± 32.5 | < 0.01 |
Preoperative Foley placement | 49 (39.2%) | 5 (100%) | 44 (40%) | 3 (10.34%) | 7 (23.33%) | ||
Transfusion rate | 4 (3.2%) | 1 (6.67%) | 3 (2.72%) | 4 (13.79%) | 8 (26.67%) | ||
Reduction ratio of the PSA level 3 months postoperatively (%) | 85.59 ± 14.92 | 39.21 ± 44.95 | < 0.0001 | 70.22 ± 28.86 | 0.0047 | ||
Reduction ratio of the estimated prostate size postoperatively (%) | 74.17 ± 11.27 | 47.24 ± 16.20 | < 0.0001 | 49.01 ± 17.79 | < 0.0001 |